v3.26.1
COLLABORATION ARRANGEMENTS (Details)
 1 Months Ended 12 Months Ended
Dec. 31, 2018
CNY (¥)
Dec. 31, 2025
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2021
CNY (¥)
Apr. 30, 2022
USD ($)
Mar. 31, 2022
USD ($)
Feb. 28, 2021
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative                    
Revenues   $ 7,670,902 $ 103,204 $ 18,111,491            
Guilin Sanjin Pharmaceutical Co., Ltd. License Agreement                    
Collaborative Arrangement and Arrangement Other than Collaborative                    
Upfront cash payment received | ¥ ¥ 10,000,000                  
Agreed period for not to grant rights associated with antibodies to third parties 3 years                  
Dragon Boat Biopharmaceutical (Shanghai) Limited License Agreement                    
Collaborative Arrangement and Arrangement Other than Collaborative                    
Agreed period for not to grant rights associated with antibodies to third parties   3 years                
Upfront fee received | ¥             ¥ 4,000,000      
Milestone fee received | ¥             ¥ 4,000,000      
Revenues   $ 0 0 0            
Exelixis Inc Agreement                    
Collaborative Arrangement and Arrangement Other than Collaborative                    
Upfront cash payment received         $ 8,500,000 $ 11,000,000        
Upfront fee received       5,500,000            
Milestone fee received       3,000,000            
Revenues   0 $ 0 9,600,000   $ 1,100,000        
Payment of upfront-refundable fee               $ 1,100,000   $ 11,000,000
Milestone payments receivable based on development and regulatory milestones                   127,500,000
Milestone payments receivable based on sales                   $ 262,500,000
Milestone payment received       3,000,000 3,000,000          
Exelixis Inc Agreement | Delivery of data packages and achievement of initial target milestone                    
Collaborative Arrangement and Arrangement Other than Collaborative                    
Revenues       8,500,000            
Exelixis Inc Agreement | Delivery of additional masked antibodies                    
Collaborative Arrangement and Arrangement Other than Collaborative                    
Revenues       $ 1,100,000            
Sanofi Agreement                    
Collaborative Arrangement and Arrangement Other than Collaborative                    
Upfront cash payment received         $ 17,500,000          
Revenues   2,149,817                
Payment of upfront-refundable fee                 $ 17,500,000  
Percentage of revenue         100          
Milestone payments receivable based on development and regulatory milestones                 173,500,000  
Milestone payments receivable based on sales                 $ 450,000,000  
Third Arc Agreement                    
Collaborative Arrangement and Arrangement Other than Collaborative                    
Upfront cash payment received   5,000,000                
Payment of upfront-refundable fee   5,000,000                
Commercial based milestone   $ 840,000,000